Sun Pharmaceutical Industries Ltd. Share Price

Overview

Sun Pharmaceutical Industries Ltd. share price is currently ₹1,875.33, down by - ₹11.85 (0.63%) from its previous closing price of ₹1,887.18. The share price has gained 8.82% over the past month and gained 8.49% over the past year. The stock's 52-week low and high are ₹1,556.92 and ₹2,009.08, respectively. Sun Pharmaceutical Industries Ltd. has a market capitalisation of ₹ 4,56,593.45 Cr. The share price was last updated on 20 Nov 2026, 03:58 PM IST.

Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
 ₹0.00
- ₹11.85
0.63%
Healthcare
 ₹0.00(%)1D

Updated: 20 Nov 2026, 03:58:37 pm IST

Market Data

Open Price

 ₹1,890.12

Prev. Close

 ₹1,887.18
 ₹1,873.22

Day Low

 ₹1,900.20

Day High

 ₹1,556.92

52 Week Low

 ₹2,009.08

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

41.03

Sector PE

45.96

PB Ratio

5.38

Sector PB

6.03

EPS

45.71

Dividend Yield

0.91

Today's Volume

1.995 M

5 Day Avg. Volume

1.814 M

PEG Ratio

8.14

Market Cap.

₹ 4,56,593.45 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 500% at ₹5/Share
07-Jul-202607-Jul-2026
DividendsInterim Dividend of 1100% at ₹11/Share
05-Feb-202605-Feb-2026
DividendsFinal Dividend of 550% at ₹5.5/Share
07-Jul-202507-Jul-2025
DividendsInterim Dividend of 1050% at ₹10.5/Share
06-Feb-202506-Feb-2025

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
SBI Nifty 50 ETF2.05 Cr
2.06 Cr
(0.16%)
SBI BSE Sensex ETF1.45 Cr
1.46 Cr
(0.65%)
ICICI Prudential Value Fund - Growth1.38 Cr
1.38 Cr
no change
ICICI Prudential Aggressive Hybrid Fund - Growth98.53 Lac
98.53 Lac
no change
HDFC Balanced Advantage Fund - Growth87.46 Lac
87.46 Lac
no change

About Sun Pharmaceutical Industries Ltd. 👋

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Shree Dhanraksha Securities

Shree Dhanraksha Securities

17 Nov • 11:28 AM · SEBI-Registered Analyst

Pharmaceuticals Sector - Sun Pharmaceutical Industries

SUNPHARMA Pharmaceutical companies are influenced by product launches, regulatory approvals, research pipelines, generic-drug competition, US-market exposure and litigation. Sun Pharmaceutical Industries remains one of India's prominent healthcare companies and a Nifty 500 constituent. A very recent company update is particularly interesting: on 23 September 2026, Sun Pharma announced the launch of C Taro-Methylphenidate ER, described by the company as the first and only bioequivalent product to Concerta with an osmotic delivery system. The company has also disclosed recent developments relating to litigation settlements, credit ratings and international business activities. The key lesson is that pharma stocks should be studied through both financial results and their product/regulatory pipeline.

See More
Lovelesh Sharma

Lovelesh Sharma

15 Nov • 10:30 PM · SEBI-Registered Analyst

Sun Pharma: Recovery Reclaims ₹1,880 Pivot

Sun Pharma has staged a sharp recovery from the recent correction low and has reclaimed the ₹1,880 pivot area. The move shows strong buying interest after the decline, with price quickly recovering from the lower zone and returning to the middle of its prior trading range. The ₹1,880 level is now the key short-term pivot. Sustaining above it can help the stock build a higher base and keep the recovery structure intact. The latest session is testing this area after a fast upward move, so some consolidation near the current level would be normal before any further breakout attempt. The immediate resistance is near ₹1,915, the latest high. A sustained move above ₹1,915 can strengthen the recovery and open room towards the prior swing-high zone. On the downside, ₹1,840 is the first support, followed by ₹1,800. The Z-score has moved back into positive territory, supporting the rebound, but price needs to hold above ₹1,880 to maintain its improving structure. SUNPHARMA

See More
Threetrend Research

Threetrend Research

15 Nov • 5:41 PM · SEBI-Registered Analyst

Sun Pharma is showing a positive technical structure

SUNPHARMA Sun Pharma is showing a positive technical structure as the stock is currently trading at ₹1,880, comfortably above all four important EMAs: 21 EMA (₹1,827.9), 50 EMA (₹1,828.7), 100 EMA (₹1,837) and 200 EMA (₹1,818.3). This indicates improving bullish momentum and suggests that buyers are maintaining control. Recently, the stock witnessed a sharp recovery from the ₹1,740–1,760 support zone and moved towards ₹1,940–1,950, indicating strong buying interest. The ₹1,820–1,840 zone is now an important support area, where multiple EMAs are clustered. On the upside, ₹1,920–1,950 is an immediate resistance zone, followed by ₹2,000. Sustaining above the EMA cluster can keep the recovery structure positive, while a decisive breakout above resistance may strengthen the next upward move. Sun Pharma continues to benefit from strong domestic formulations and specialty medicines businesses. In Q2 FY27, revenue increased approximately 11.9% year-on-year, while India business grew 17.3%, reflecting healthy demand and product launches. Its specialty portfolio received another boost as the US FDA approved ILUMYA for treating adults with active psoriatic arthritis on October 30, 2026. However, the company reported pressure in its US business, with sales declining 8.2%, and EBITDA margin stood at 29.3%. One concern is the regulatory action involving its Assam facility, where ophthalmic product manufacturing was halted following quality-related observations; the company has submitted corrective measures for regulatory review. Overall, domestic growth and specialty medicines provide positive long-term support, but regulatory developments and US business performance remain important factors to monitor.

See More
Jeet B Bhayani

Jeet B Bhayani

14 Nov • 11:53 PM · SEBI-Registered Analyst

NPPA Anti-Cancer Drug Price Revision Overview

Revised maximum retail prices (MRPs) for 1,364 anti-cancer formulations came into effect on November 9, 2026, following price-control interventions implemented by the National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals. Expected to yield annual consumer savings of approximately ₹3,540.38 crore ($372.48 million), the measure stems from trade margin rationalizations imposed across 137 anti-cancer drugs based on recommendations from a Directorate General of Health Services (DGHS) Expert Committee constituted on October 17, 2026. According to the Ministry of Chemicals and Fertilizers, 85 pharmaceutical manufacturers had officially submitted revised MRPs covering 1,364 formulations across 121 molecules as of November 8, 2026. The regulatory price revisions have slashed costs by more than 50% across 679 brands, with the steepest individual price reduction reaching 96.45%. Under the directive, retail chemists and hospital pharmacies are strictly prohibited from charging above the notified MRPs, which patients can verify via updated packaging labels, the Pharma Sahi Daam mobile application, or the official NPPA portal. To enforce compliance and curb overcharging, grievances can be lodged through the Pharma Jan Samadhan platform or the toll-free NPPA helpline (1800-111-255)—a move designed to significantly improve cancer care affordability and ease out-of-pocket financial strain on patients and their families. SUNPHARMA

See More
ShubInvest

ShubInvest

13 Nov • 12:13 PM · SEBI-Registered Analyst

Market Falls, But Pharma Shows Strength!

Imagine the stock market opening with heavy pressure. The Sensex and Nifty move lower, while realty and auto shares face selling pressure. While most sectors struggle, the pharmaceutical sector shows strength. SUNPHARMA emerges as the best-performing Sensex stock during the opening session. When inflation rises and investors become worried about interest rates, market sentiment can turn negative. During such periods, pharmaceutical businesses may attract attention because healthcare demand is often less sensitive to economic conditions. - Strong presence in the pharmaceutical industry. - Healthcare demand supports long-term industry relevance. - Pharma stocks showed relative strength during the market decline. - Its performance highlights the importance of sector analysis. However, one positive trading session does not guarantee future returns. Investors should study company earnings, valuations, business performance and risks before making decisions. When markets fall, defensive sectors may attract attention, but investors should study earnings, valuations, debt and strength before making decisions.

See More
Threetrend Research

Threetrend Research

11 Nov • 1:59 PM · SEBI-Registered Analyst

SPARC has encouraging revenue growth and potential

SPARC Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical R&D company focused on developing innovative medicines and speciality treatments. In its latest Q2 FY27 results, the company reported revenue from operations of approximately ₹30.03 crore, up 282% year-on-year, but still reported a consolidated net loss of ₹24.39 crore, indicating that profitability remains a challenge. For H1 FY27, revenue increased approximately 300% year-on-year to ₹69.95 crore. An important development was the company's sale of a USFDA Priority Review Voucher (PRV) for USD 195 million in April 2026, following its grant for Sezaby. However, this generated exceptional income and should not be considered recurring operating revenue. Going forward, investors should monitor its drug-development pipeline, regulatory approvals, revenue growth and reduction in R&D-related losses. SPARC has encouraging revenue growth and potential from its research pipeline, but consistent profitability is yet to be established. A strong technical trend above all four EMAs would indicate improving market sentiment, while fundamental improvement needs to be confirmed through sustainable earnings growth.

See More

News & Events

Frequently Asked Questions

What is the share price of Sun Pharmaceutical Industries Ltd.?

What is the market cap of Sun Pharmaceutical Industries Ltd.?

Should I buy Sun Pharmaceutical Industries Ltd. stock now?

What is the 52 week high and low of Sun Pharmaceutical Industries Ltd.?

Is the Sun Pharmaceutical Industries Ltd. stock good to buy?

Is Sun Pharmaceutical Industries Ltd. a good buy for the long term?

Is Sun Pharmaceutical Industries Ltd. overvalued or undervalued?

What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd.?

Start Now